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a  b  s  t  r  a  c  t
Objectives:  Although  exponential  growth  is  assumed  for lung  cancer,  this  has  never  been  quantiﬁed  in
vivo.  Aim  of this  study  was  to evaluate  and quantify  growth  patterns  of lung  cancers  detected  in  the
Dutch-Belgian  low-dose  computed  tomography  (CT) lung  cancer  screening  trial  (NELSON),  in order  to
elucidate  the  development  and  progression  of  early  lung cancer.
Materials  and  methods:  Solid  lung  nodules  found  at ≥3  CT  examinations  before  lung cancer  diagnosis
were  included.  Lung  cancer  volume  (V)  growth  curves  were  ﬁtted  with  a single  exponential,  expressed
as V  =  V1 exp(t/), with  t  time  from  baseline  (days),  V1 estimated  baseline  volume  (mm3), and   estimated
time  constant.  The  R2 coefﬁcient  of  determination  was  used  to evaluate  goodness  of  ﬁt. Overall  volume-
doubling  time  for the  individual  lung  cancer  is  given  by    * log(2).
Results:  Forty-seven  lung  cancers  in  46  participants  were  included.  Forty  participants  were  male  (87.0%);
mean  age  was  61.7  years  (standard  deviation,  6.2 years).  Median  nodule  size  at  baseline  was 99.5 mm3
(IQR:  46.8–261.8  mm3). Nodules  were  followed  for a median  of  770  days  (inter-quartile  range:  383–1102
days)  before  lung  cancer  diagnosis.  One  cancer  (2.1%)  was  diagnosed  after  six CT examinations,  six  cancers
(12.8%) were  diagnosed  after ﬁve  CTs,  14  (29.8%)  after  four  CTs,  and  26 cancers  (55.3%)  after  three  CTs.
2Lung  cancer  growth  could  be  described  by  an  exponential  function  with  excellent  goodness  of  ﬁt  (R
0.98).  Median  overall  volume-doubling  time  was  348  days  (inter-quartile  range:  222–492 days).
Conclusion:  This  study  based  on  CT lung  cancer  screening  provides  in  vivo  evidence  that  growth  of  can-
cerous  small-to-intermediate  sized  lung  nodules  detected  at low-dose  CT  lung  cancer  screening  can  be
described  by an exponential  function  such  as  volume-doubling  time.
© 2017  Elsevier  B.V.  All  rights  reserved.Abbreviations: CI, conﬁdence interval; CT, computed tomography; IQR, inter-quart
andomized lung cancer screening trial; V, volume (mm3); VDT, volume-doubling time (d
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. Introduction
A tumor starts from a single cell that approximately doubles in
olume with each cell division. Based on this principle, a theoreti-
al exponential model for tumor growth was already introduced
n 1956 [1]. It is assumed that this model also ﬁts lung cancer
rowth, however this has not been proven in clinical practice. A
ait-and-see principle is not commonly used when lung cancer
s suspected, because of the aggressiveness of the disease. In vivo
nformation on lung cancer growth patterns, from small nodules
arely detectable by imaging techniques (∼15 mm3) to histologi-
ally proven lung cancers, is therefore scarce. With the introduction
f low-dose computed tomography (LDCT) lung cancer screening,
mall-to-intermediate sized nodules, usually benign, are found in
he majority of screenees [2–4]. Follow-up CTs are performed to
etermine nodule growth, in order to differentiate between benign
nd malignant nodules. Screening provides a unique opportunity
o analyze lung cancer growth patterns in more detail. So far, there
s one study in which growth dynamics of untreated, subclinical
creen-detected lung cancers on CT examinations were evaluated
5]. They concluded that most of the eighteen lung cancers studied
id not show exponential growth [5].
Currently, lung cancer screening by LDCT is already being imple-
ented in daily practice in the United States. In Europe, decisions
egarding the introduction of lung cancer screening will depend on
he ﬁnal results of ongoing trials [6]. A challenge in CT lung can-
er screening is the high rate of false-positive screen results. At
rst detection, nodule management is based on nodule size. In the
ollow-up of both screen-detected nodules and nodules inciden-
ally detected in routine clinical care, accurate detection of nodule
rowth is essential to reduce false-negative and false-positive
creen results. One way to determine nodule growth is by calcu-
ating the volume-doubling time (VDT). However, this biomarker
s based on the assumption that lung cancer grows exponentially.
In the study by Lindell et al., mentioned above, growth curves
ere based on diameter-based estimated volumes [5]. Further-
ore, lung cancer growth patterns were only visually evaluated
nd not quantiﬁed. In the Dutch-Belgian randomized lung cancer
creening trial (Dutch acronym: NELSON), nodule volumes were
enerated semi-automatically by software; a far more accurate way
o determine nodule size [7,8]. In addition, for subsequent screen-
ng rounds VDTs were determined based on nodule volume [7,8].
his allows detailed evaluation of lung cancer growth, including
uantiﬁcation of growth curves. The purpose of this study was  to
valuate and quantify growth patterns of lung cancers detected in
DCT lung cancer screening, in order to elucidate the development
nd progression of early lung cancer.
. Materials and methods
.1. Participants
The Dutch Ministry of Health approved the NELSON trial
ISRCTN63545820). Participants provided written informed con-
ent. Recruitment and selection criteria have been published [9].
articipants (heavy (ex-)smokers, aged 50–75 years) were random-
zed to no screening (n = 7907) or screening (n = 7915) by chest LDCT
t baseline (1st round), after 1 year (2nd round), 3 years (3rd round)
nd 5.5 years (4th round) [10].
For this sub-study, solid lung nodules diagnosed as lung cancer
fter three or more subsequent LDCT scans with successful semi-
utomated volume measurements were selected. Two  lung cancers
ere excluded because of lack of a third volume measurement due
o failing volume measurements with a volume too large for semi-
utomated measurements at the ﬁnal CT. Furthermore, subsolidancer 108 (2017) 48–54 49
lung cancers were excluded, since the Syngo LungCARE© software
package was not able to calculate the volume of sub-solid nod-
ules (1.9% of all non-calciﬁed nodules). Growth curves of nineteen
subsolid NELSON lung cancers have been published elsewhere [33].
2.2. Equipment and image reading
Sixteen-multi-detector (MD)CT scanners or, in later rounds,
64-MDCT scanners were used (Sensation-16 or Sensation-64,
Siemens Medical Solutions, Forchheim, Germany, or Mx8000 IDT
or Brilliance 16P or Brilliance 64, Philips Healthcare, Best, The
Netherlands). Scanning parameters have been published, and were
equal for all screenings [11,12].
Lung nodule evaluation was  performed with software for
semi-automated volume measurements (LungCARE© [Somaris/5
VA70C-W, Siemens Medical Solutions]) [11]. In the ﬁrst two  screen-
ing rounds, CT images were read twice [11,12]; if measured volume
differed between the independent readers, second reader’s mea-
surements were used. In the next screening rounds, one radiologist
with at least 6 years experience read the examinations.
Nodule margin was classiﬁed as smooth, lobulated, spiculated
or irregular, based on the three-dimensional nodule segmentation
[13–15].
2.3. Nodule management protocol
The nodule management protocol was previously described
[11]. Screenings could lead to three outcomes: negative result (vol-
ume  <50 mm3; implication: next screening round), indeterminate
result (volume 50–500 mm3; short-term follow-up CT after 6–12
weeks) or positive result (volume >500 mm3; referral to pulmo-
nologist). For previously detected nodules, at least 25% volume
increase led to VDT assessment. Nodules with VDT <400 days
resulted in a positive result [11]. Positive screenees were referred
to a pulmonologist for diagnostic workup. They received usual care
according to (inter)-national guidelines [16–18]. NELSON’s chief
pathologist reassessed histological specimens of positive scree-
nees.
2.4. Growth curves and statistical analyses
Lung cancer volume (V) growth curves were ﬁtted as function
of time t, assuming an exponential growth pattern, using






with t time from baseline, V1 the volume at baseline in mm3 and
 the time constant (days). Curves were ﬁtted using a least square
estimation procedure, returning estimates for V1 and . As mea-
sure for the goodness of ﬁt, R2 coefﬁcient determination was  used,
where a perfect ﬁt results in R2 = 1. Normalized growth curves,
including all lung cancers, were created by plotting normalized vol-





Overall VDT per lung cancer case was  calculated from the estimated
time constant  using
VDT =  · log(2) (3)Difference in overall VDT between nodules detected at different
numbers of screening CT examinations before diagnosis of lung
cancer was  tested by the Kruskal–Wallis test. P ≤ 0.05 was  consid-
ered to indicate statistical signiﬁcance. Analyses were performed
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tig. 2. CT examinations with semi-automated volume measurements of a lung no
rew  from 17.0 mm3 at baseline to 88.3 mm3 at time of referral after follow-up ex
odule  is shown in Fig. 3b.




In total, 46 participants with 47 screen-detected lung cancers
ased on a solid lung nodule found at ≥3 LDCTs before referral to a
ulmonologist, were included. Mean age of these participants was
1.7 years (standard deviation, 6.2 years), 40 were male (87.0%).
wenty-seven participants (58.7%) were current smokers; mean
moked pack-years was 47.6 (21.1). Nodules were followed for
 median of 770 days (IQR: 383–1102 days), before lung cancer
as diagnosed. Median nodule size at baseline was 99.5 mm3 (IQR:
6.8–261.8 mm3). One cancer (2.1%) was referred for work-up and
iagnosed after six CT examinations, six (12.8%) after ﬁve CTs, 14
29.8%) after four CTs, and 26 cancers (55.3%) were diagnosed after
hree CT examinations.iagnosed as being malignant after four subsequent CT examinations. This nodule
tion in the second screening round, 1.5-years after baseline. Growth curve of this
3.2. Cancer characteristics
Lung cancer characteristics are presented in Table 1 . At time of
diagnosis, the majority of lung cancers was stage I (35/47, 74.5%).
Most cancers were adenocarcinoma (38/47, 80.9%). Furthermore,
four squamous cell carcinomas (8.5%), one large cell carcinoma
(2.1%), and one atypical carcinoid (2.1%) was  found. Two  cancers
(4.2%) were diagnosed as non-small cell lung cancer not other-
wise speciﬁed. One nodule (2.1%) was  treated as a lung cancer by
stereotactic radiotherapy, without ﬁnal histological diagnosis.
3.3. Growth patterns
Good ﬁt to exponential growth was conﬁrmed by the high R2
coefﬁcient of determination for the individual cancer growth curves
(median 0.98; IQR: 0.94–0.99). An overview of the R2 coefﬁcient of
determination for the individual lung cancers is shown in Fig. 1.
R2 of pulmonary nodules found at ≥4 CT examinations before
lung cancer diagnosis did not differ signiﬁcantly from R2 of nod-
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Fig. 3. Examples of lung cancer growth pattern. (a) Growth curve of a lung nodule
that was detected on six subsequent CT examinations before lung cancer diagnosis
was  made. The nodule grew from 264.8 mm3 at baseline to 1038.8 mm3 at time of
referral after the fourth screening round, 5.5-years after baseline. The exponential
ﬁt  (using Eq. (1)), is nearly perfect (R2 = 0.97), with estimated initial volume
V1 = 276.5 mm3 and time constant  = 1484 days, resulting in an overall volume-
doubling time (VDT) of 1027 days. (b) Growth curve of a lung nodule diagnosed
as  being malignant after four subsequent CT examinations. This nodule grew from
17.0 mm3 at baseline to 88.3 mm3 at time of referral after follow-up examination in
the second screening round, 1.5-years after baseline. The ﬁtted exponential (with
Table 1
Characteristics of solid lung cancers diagnosed after ≥3 CT examinations.
Characteristics Lung cancer nodule (n = 47)
Histological type (n (%))
Adenocarcinoma 38 (80.9)
Squamous cell carcinoma 4 (8.5)
Large cell carcinoma 1 (2.1)
Carcinoid 1 (2.1)
NSCLC, not speciﬁed 2 (4.2)
No histology obtained 1 (2.1)
Cancer stage (n (%))
IA 33 (70.2)






Follow-up time after baseline (days)





Irregular 6 (12.8)Note: Unless otherwise indicated, data are numbers of nodules, with percentages in
parentheses. IQR, inter-quartile range.
ules found at three CT examinations (median 0.97 [IQR: 0.91–0.99]
versus 0.99 [IQR: 0.96–1.00], respectively [p = NS]).
In Figs. 2 and 3, examples of, respectively, CT images and growth
patterns of lung cancers are shown. Not all cancers showed a
growth pattern with fast growth immediately from ﬁrst detection;
ﬁve nodules showed an almost constant (small) volume for at least
500 days before growth expansion and diagnosis of lung cancer, see
Fig. 3c. Still, growth patterns of these nodules could be described by
the exponential function with an excellent ﬁt (median 1.00 [IQR:
0.98–1.00]). After normalization of volume measurements and of
time from baseline for the individual lung cancers, linear growth on
a logarithmic scale was found, indicative of an exponential growth
pattern (Fig. 4).
3.4. Overall volume-doubling times
Median overall VDT from baseline until last screen evalua-
tion before cancer diagnosis was 348 days (IQR: 222–492); range
80–4271 days. When comparing overall VDT of nodules followed
for a different number of CT examinations before lung cancer diag-
nosis, VDT turned out to be lower in participants who  received
less CTs (median 270 days [IQR: 182–357 days] in case of three
CTs, median 368 days [IQR: 305–554 days] in case of four CTs, and
median 960 days [IQR: 462–1039 days] in case of ﬁve or six CTs
[p < 0.01]). An overview of the number of lung cancers per overall
VDT is shown in Fig. 5.
3.5. Non-ﬁtting growth curves
Although most lung cancers showed an excellent ﬁt to an expo-
nential curve, there were some exceptions. Two cases with R2 < 0.5
were visually re-evaluated. In one cancer, semi-automated volume
measurements were not accurate since this nodule was pleural
attached. In this case, the software was not able to differentiate
R2 = 0.99) returns V1 = 20.2 mm3 and  = 334 days with overall VDT  = 232 days. (c)
Example of a cancer showing a period of constant small volume before growth
expansion. Shown is the growth curve of a lung nodule that was detected on ﬁve sub-
sequent CT examinations before lung cancer diagnosis was made. The nodule grew
from 65 mm3 at baseline to 5042 mm3 at time of referral after the fourth screening
round, 5.5-years after baseline.
52 M.A. Heuvelmans et al. / Lung C
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axis represents normalized nodule volume (V/V1) on a logarithmic scale. The x-axis



















iig. 5. Overall volume-doubling time (VDT) for 46 lung cancers. One case with
utlier VDT of 4271 days was  not depicted in this ﬁgure.
leura from nodule and underestimated nodule volume, and the
articipant was referred based on visual nodule growth. The second
ase comprised a participant with a double tumor. The participant
eceived a positive test result based on a larger, fast-growing nod-
le. At time of surgery, however, also a smaller nodule in another
obe was resected. This nodule turned out to be lung cancer as well.
. Discussion
We  show that growth of lung cancers, detected in a LDCT lung
ancer screening trial, usually can be described by an exponential
rowth function. Information on growth patterns of lung cancer
s of great importance, since after the introduction and continual
mprovement of CT, and the more recent introduction of lung can-
er screening by LDCT, a large number of nodules with smaller
imensions is detected, most being benign [2–4]. For those small-
o-intermediate sized pulmonary nodules, the deﬁnitive diagnosis
till remains a dilemma for radiologists. As morphologic nodule
valuation alone is not sufﬁcient [19], follow-up is necessary. For
ntermediate-sized nodules, the decision for (invasive) workupancer 108 (2017) 48–54
usually depends on growth rate. The malignant potential of these
nodules is often suggested by rapid growth rate in terms of a short
VDT [4,20]. The use of VDT, however, is based on the assumption of
an exponential growth pattern of lung cancers.
This multi-center study is one of the ﬁrst to actually quantify
and conﬁrm, not only by visual analysis, that growth in early lung
cancers can be described by using an exponential function, and
indicates that lung cancer growth can be monitored by the VDT as
imaging biomarker. It provides unique insight in the natural behav-
ior of lung cancer; a type of malignancy that, untreated, usually
cannot be followed over a longer time period in clinical care.
The median overall VDT of lung cancers in this study was  348
days (IQR: 222–492 days), and comparable to VDTs reported in
other lung cancer screening trials [21–23]. Since at least three
monitoring points are necessary for growth pattern evaluation,
lung cancers referred after the ﬁrst short-term follow-up CT were
not included in this analysis. The latter nodules usually show fast
growth rates below 232 days [24].
It has been suggested that lung cancers grow according to a
Gompartzian growth model, which means that growth rate slowly
decreases to reach a certain plateau, after a period of exponential
growth [25,26]. In the current study, in which the majority of lung
cancers was  early stage, we found that cancers showed exponential
growth throughout the observational period. A decrease in growth
rate was not observed possibly because tumors were too small to
reach that point at diagnosis and participants were treated after
lung cancer diagnosis was made.
Lindell et al. [5] were the ﬁrst to plot growth curves of 18
lung cancers diagnosed after at least four serial CT examina-
tions. It was  concluded that lung cancer growth was not limited
to an exponential pattern, and thus questioned the application
of VDT as part of nodule management algorithms in LDCT lung
cancer screening. That study, however, had some limitations.
First, the majority of studied lung cancers (n = 11; 61%) was sub-
solid. Volume for all nodules was calculated based on nodule
diameter (V = 1/6 *  * [ab2], with a the longest and b the per-
pendicular diameter). Especially in sub-solid nodules, but also in
solid nodules, diameter measurements are less accurate than vol-
ume  measurements [7,8]. Furthermore, the study used relatively
thick slice-thickness (3.75–5 mm)  and large reconstruction inter-
vals (5 mm)  that may  have contributed to even more imprecise
diameter measurements, especially for sub-centimeter nodules. In
the NELSON study, slice thickness of 1.0 mm with reconstruction
interval of 0.7 mm was  used to provide isometric voxels for accurate
semi-automated volume measurements. These semi-automated
measurements were found to be highly reproducible for the large
majority of solid nodules, also in phantom studies [27–29], with
high reader agreement and volume differences >15% between two
readers in only 4% of solid nodules [27–29]. Besides, in Lindell’s
study lung cancer growth curves were plotted and visually evalu-
ated, but growth patterns were not quantiﬁed. They only included
lung cancers diagnosed after ≥4 CT examinations, since they stated
that four was  the minimal number of monitoring points required
for generating growth curves [5]. We have included cancers diag-
nosed after three CTs as well. We found that the exponential ﬁt in
terms of the R2 coefﬁcient of determination of lung cancers diag-
nosed after ≥4 CTs was  comparable to lung cancers diagnosed after
three CTs.
A second study evaluated growth curves of thirteen primary
lung cancers with at least three serial CT examinations [30]. Nodule
volumes were derived semi-automatically. Analysis of lung cancer
growth curves was limited, and restricted to a plot of the growth
curves on a log scale, only analyzed visually. Growth rates appeared
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In our study, ﬁve of 47 lung cancers showed an almost constant
small) volume for at least 500 days before growth expansion and
iagnosis of lung cancer. It is known that the carcinogenic process
eading to lung cancer evolves slowly depending on the accumula-
ion rate of DNA aberrations in the ancestor cells, for over 20 years
31]. In a screening setting, incidental detection of a slower growing
ancer is more likely than it is in general practice. Another cause
or the period of constant volume may  be a proliferation rate in
alance with the apoptotic rate.
In lung cancer screening programs and in clinical practice, nod-
le management is not only based on nodule size at ﬁrst detection,
ut also on change in size in case of a prevalence nodule. In
ost diameter-based nodule management protocols, including the
ecently published Lung-RADS guideline [32], nodule growth is
eﬁned as a ﬁxed increase in diameter, regardless of the time inter-
al between two subsequent screenings. Our study suggests that
his linear method cannot accurately represent the rate of nodule
rowth. A linear method might lead to false-negative classiﬁcation
f small, fast-growing cancers at short-term follow-up.
The major limitation of this study is the fact that only growth
atterns of relatively slow-growing lung cancers (about one-ﬁfth
f total screen-detected cancers) could be evaluated, since more
ggressive lung cancers did not have follow-up of at least three CT
xaminations but were earlier referred to a pulmonologist, which
ay  limit the generalizability of our results. Compared to the over-
ll group of screen-detected cancers in the ﬁrst to third NELSON
ound, this study comprised more adenocarcinomas (80.9% versus
1.2%), known as a relatively slower growing type of lung cancer,
hereas no small cell lung cancers (4.8% of total cancers), usually
ast-growing and advanced staged, were followed by at least three
Ts. Notwithstanding, the percentage stage I cancers in this study
74.5%) was comparable to the percentage stage I cancers in the
verall group of cancers in the ﬁrst to third screening round (70.9%).
.1. Conclusion
This study based on CT lung cancer screening provides in vivo
vidence that growth of cancerous small-to-intermediate sized
ung nodules detected at LDCT lung cancer screening can be
escribed by an exponential function such as volume-doubling
ime.
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